乙肝病毒相关性肾炎 中国就医指南

Hepatitis B virus-associated glomerulonephritis (HBV-GN) is a rare but clinically significant immune-complex-mediated kidney disease triggered by chronic hepatitis B virus (HBV) infection. It predominantly manifests as membranous nephropathy (MN) or, less commonly, membranoproliferative glomerulonephritis (MPGN), characterized by HBV antigen deposition—particularly hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)—within the glomerular basement membrane and mesangium. Pathogenesis involves persistent viral replication leading to formation of circulating immune complexes that deposit in renal tissue, activating complement cascades and inducing podocyte injury, proteinuria, and progressive glomerular damage. Unlike primary glomerulonephritis, HBV-GN is directly linked to virological activity and host immune dysregulation; antiviral therapy often reverses histopathological changes, underscoring its unique treatability among secondary GN etiologies. Epidemiologically, HBV-GN is endemic in regions with high HBV prevalence—including East Asia, sub-Saharan Africa, and parts of Latin America—with an estimated incidence of 1–5% among chronically HBV-infected adults presenting with nephrotic syndrome. In China, where chronic HBV carriage affects ~5–7% of the population, HBV-GN accounts for up to 30% of pediatric nephrotic syndrome cases and ~10–15% of adult-onset membranous nephropathy. Key risk factors include childhood HBV acquisition (vertical transmission), HBeAg positivity, high serum HBV DNA load (>2,000 IU/mL), male sex, and genetic susceptibility (e.g., HLA-DRB1*07 and *09 alleles). Notably, immunosuppressants like corticosteroids alone may exacerbate viral replication and are contraindicated without concurrent antiviral coverage. Quality of life impact is substantial: patients frequently experience fatigue, edema, recurrent infections, and psychological distress due to chronic illness, dietary restrictions, and treatment burden. Proteinuria and hypoalbuminemia increase thromboembolic and cardiovascular risks, while delayed diagnosis can lead to irreversible fibrosis and progression to end-stage kidney disease (ESKD). Early recognition—via serologic HBV screening in all glomerulonephritis patients, especially in endemic areas—is critical. With timely antiviral-based regimens, over 70% achieve complete or partial remission of proteinuria within 6–12 months, preserving long-term renal function and markedly improving functional status and mental well-being.

# 乙肝病毒相关性肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：HBV-DNA阳性、蛋白尿＜3.5g/d、eGFR＞60mL/min/1.73m²、无显著新月体或间质纤维化者。

• •抗病毒治疗（一线）：恩替卡韦（0.5mg/d）或替诺福韦酯（300mg/d），年药费：2,400–4,800元
• •免疫调节+降蛋白：小剂量糖皮质激素（泼尼松≤0.3mg/kg/d）+雷公藤多苷片，年药费：1,200–3,000元
• •基础检查（每3个月）：HBV-DNA定量、肝肾功能、24h尿蛋白、肾脏超声，单次检查费：850–1,300元

二、肾活检及介入诊疗方案

适用条件：临床诊断存疑、蛋白尿＞3.5g/d或eGFR快速下降者。

• •经皮肾穿刺活检（含病理+免疫荧光+电镜）：4,200–6,500元（含术前凝血四项、B超定位、术后监护）
• •术前必查：乙肝五项、HBV-DNA、PTA、血小板计数、双肾彩超，合计：680–950元

三、特殊复杂/晚期方案

适用情形：HBV再激活、膜性肾病Ⅳ期、CKD 4–5期或合并肝硬化失代偿。

• •多靶点联合（TDF+干扰素α-2a皮下注射+ACEI/ARB）：年综合费用：18,000–32,000元
• •终末期需血液透析者：透析费（含乙肝专机）：420–480元/次，年均约12–15万元

四、方案快速选择指南

• •预算有限（＜5k/年）：优选恩替卡韦+定期随访；
• •中等预算（1–3万/年）：加用雷公藤+规范肾活检明确病理；
• •重症/耐药/进展快者：立即启动TDF+个体化免疫干预，纳入肝肾联合管理。